Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Aosaikang Pharma Signs Deal with New Zealand Diabetes Company

publication date: Jan 31, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangsu Aosaikang Pharmaceutical (ASK) of Nanjing purchased a 5% stake in a New Zealand pharma, Living Cell Technologies, for $1.7 million. LCT’s major product, Diabecell, is a technology that implants encapsulated islet cells from pigs into the livers of diabetic patients. The product is in a Phase II clinical trial in New Zealand. As part of the investment, ASK will have an option on China rights to the technology. More details....



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners